Drug intelligence / Profile preview

JNJ-1459

Development stage: Discontinued
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

JNJ-1459 is an oral small-molecule interleukin-17 (IL-17) inhibitor developed by Johnson & Johnson/Janssen as a targeted therapy for moderate to severe plaque psoriasis. It is designed to inhibit IL-17A binding to its receptor, thereby blocking downstream pro‑inflammatory signaling pathways that drive keratinocyte activation and psoriatic plaque formation.[1][3][5][10] As an antipsoriatic agent and new molecular entity, JNJ-1459 advanced to phase 2 clinical development in plaque psoriasis before Johnson & Johnson discontinued the program as part of broader portfolio reprioritization.[1][5][6][11]

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on JNJ-1459.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-1459.

Explore the full profile